Purpose—To critically review and evaluate the science behind individual eligibility criteria
(indication/inclusion and contraindications/exclusion criteria) for intravenous recombinant …

Purpose—Our goal is to provide an overview of the current evidence about components of
the evaluation and treatment of adults with acute ischemic stroke. The intended audience is …

Background and Purpose—The authors present an overview of the current evidence and
management recommendations for evaluation and treatment of adults with acute ischemic …

Background and Purpose—The National Institutes of Health (NIH) estimates that stroke
costs now exceed $45 billion per year. Stroke is the third leading cause of death and one of …

nally, the evaluation provides historical data or other information that can be used to
establish the vascular distribution of the stroke and to provide clues about its likely …

Background and Purpose—Based on previous studies comparing different recombinant
tissue plasminogen activator (rt-PA) doses, we performed a clinical trial with 0.6 mg/kg …

Most of the contraindications to the administration of intravenous (IV) recombinant tissue
plasminogen activator (rtPA) originated as exclusion criteria in major stroke trials. These …

Background: Thrombolysis for acute ischemic stroke has remained controversial. The
Canadian Alteplase for Stroke Effectiveness Study, a national prospective cohort study, was …

Ischemic stroke represents 87% of all strokes. 1 As world-wide initiatives move forward with
stroke care, healthcare providers and institutions will be called on to deliver the most current …

Intravenous recombinant tissue plasminogen activator (r-tPA) was approved for use in acute
ischemic stroke in the United States in 1996. Approximately 2% to 5% of patients with acute …